Literature DB >> 31786986

Efficacy of Electrical Baroreflex Activation Is Independent of Peripheral Chemoreceptor Modulation.

Karsten Heusser1, Arvo Thöne2, Axel Lipp3, Jan Menne4, Joachim Beige5,6, Hannes Reuter7,8, Fabian Hoffmann1,7, Marcel Halbach7, Siegfried Eckert9, Manuel Wallbach10, Michael Koziolek10, Helge Haarmann11, Michael J Joyner12, Julian F R Paton13,14, André Diedrich15, Hermann Haller4, Jens Jordan1, Jens Tank1.   

Abstract

Arterial baroreflex activation through electrical carotid sinus stimulation has been developed for the treatment of resistant hypertension. Previous studies suggested that the peripheral chemoreflex is tonically active in hypertensive patients and may inhibit baroreflex responses. We hypothesized that peripheral chemoreflex activation attenuates baroreflex efficacy evoked by electrical carotid sinus stimulation. We screened 35 patients with an implanted electrical carotid sinus stimulator. Of those, 11 patients with consistent acute depressor response were selected (7 men/4 women, age: 67±8 years, body mass index: 31.6±5.2 kg/m2, 6±2 antihypertensive drug classes). We assessed responses to electrical baroreflex stimulation during normoxia, isocapnic hypoxia (SpO2: 79.0±1.5%), and hyperoxia (40% end-tidal O2 fraction) by measuring heart rate, blood pressure, ventilation, oxygen saturation, end-tidal CO2 and O2 fractions, and muscle sympathetic nerve activity. During normoxia, baroreflex activation reduced systolic blood pressure from 164±27 to 151±25 mm Hg (mean±SD, P<0.001), heart rate from 64±13 to 61±13 bpm (P=0.002), and muscle sympathetic nerve activity from 42±12 to 36±12 bursts/min (P=0.004). Hypoxia increased systolic blood pressure 8±12 mm Hg (P=0.057), heart rate 10±6 bpm (P<0.001), muscle sympathetic nerve activity 7±7 bursts/min (P=0.031), and ventilation 10±7 L/min (P=0.002). However, responses to electrical carotid sinus stimulation did not differ between hypoxic and hyperoxic conditions: systolic blood pressure: -15±7 versus -14±8 mm Hg (P=0.938), heart rate: -2±3 versus -2±2 bpm (P=0.701), and muscle sympathetic nerve activity: -6±4 versus -4±3 bursts/min (P=0.531). We conclude that moderate peripheral chemoreflex activation does not attenuate acute responses to electrical baroreflex activation therapy in patients with resistant hypertension. These patients provided insight into human baroreflex-chemoreflex interactions that could not be gained otherwise.

Entities:  

Keywords:  baroreflex; blood pressure; carotid sinus; hyperoxia; hypoxia

Mesh:

Year:  2019        PMID: 31786986      PMCID: PMC7158700          DOI: 10.1161/HYPERTENSIONAHA.119.13925

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  51 in total

1.  Properties of solitary tract neurones responding to peripheral arterial chemoreceptors.

Authors:  J F Paton; J Deuchars; Y W Li; S Kasparov
Journal:  Neuroscience       Date:  2001       Impact factor: 3.590

2.  Baroreflex control of muscle sympathetic nerve activity as a mechanism for persistent sympathoexcitation following acute hypoxia in humans.

Authors:  Jordan S Querido; Erica A Wehrwein; Emma C Hart; Nisha Charkoudian; William R Henderson; A William Sheel
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-09-28       Impact factor: 3.619

3.  Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial.

Authors:  John D Bisognano; George Bakris; Mitra K Nadim; Luis Sanchez; Abraham A Kroon; Jill Schafer; Peter W de Leeuw; Domenic A Sica
Journal:  J Am Coll Cardiol       Date:  2011-08-09       Impact factor: 24.094

4.  The effects of baroreflex activation therapy on blood pressure and sympathetic function in patients with refractory hypertension: the rationale and design of the Nordic BAT study.

Authors:  Daniel Gordin; Fadl Elmula M Fadl Elmula; Bert Andersson; Anders Gottsäter; Johan Elf; Thomas Kahan; Kent Lodberg Christensen; Pirkka Vikatmaa; Leena Vikatmaa; Thomas Bastholm Olesen; Per-Henrik Groop; Michael Hecht Olsen; Ilkka Tikkanen
Journal:  Blood Press       Date:  2017-06-08       Impact factor: 2.835

5.  14 nights of intermittent hypoxia elevate daytime blood pressure and sympathetic activity in healthy humans.

Authors:  R Tamisier; J L Pépin; J Rémy; J P Baguet; J A Taylor; J W Weiss; P Lévy
Journal:  Eur Respir J       Date:  2010-06-04       Impact factor: 16.671

6.  Interaction of baroreceptor and chemoreceptor reflex control of sympathetic nerve activity in normal humans.

Authors:  V K Somers; A L Mark; F M Abboud
Journal:  J Clin Invest       Date:  1991-06       Impact factor: 14.808

7.  Baroreflex control of sympathetic nerve activity in essential and secondary hypertension.

Authors:  G Grassi; B M Cattaneo; G Seravalle; A Lanfranchi; G Mancia
Journal:  Hypertension       Date:  1998-01       Impact factor: 10.190

8.  Surges of muscle sympathetic nerve activity during obstructive apnea are linked to hypoxemia.

Authors:  U Leuenberger; E Jacob; L Sweer; N Waravdekar; C Zwillich; L Sinoway
Journal:  J Appl Physiol (1985)       Date:  1995-08

Review 9.  Rostral Ventrolateral Medulla and Hypertension.

Authors:  Patrice G Guyenet; Ruth L Stornetta; Benjamin B Holloway; George M P R Souza; Stephen B G Abbott
Journal:  Hypertension       Date:  2018-09       Impact factor: 10.190

Review 10.  Does the Sympathetic Nervous System Adapt to Chronic Altitude Exposure?

Authors:  Mikael Sander
Journal:  Adv Exp Med Biol       Date:  2016       Impact factor: 2.622

View more
  3 in total

1.  Electrical carotid sinus stimulation may get lost in translation.

Authors:  Jens Jordan; Jens Tank
Journal:  Hypertens Res       Date:  2020-07-22       Impact factor: 3.872

2.  Blood Pressure-Lowering Therapy.

Authors:  Isabella Sudano; Elena Osto; Frank Ruschitzka
Journal:  Handb Exp Pharmacol       Date:  2022

3.  Sex differences in the sympathetic neurocirculatory responses to chemoreflex activation.

Authors:  Ana Luiza C Sayegh; Jui-Lin Fan; Lauro C Vianna; Mathew Dawes; Julian F R Paton; James P Fisher
Journal:  J Physiol       Date:  2022-05-12       Impact factor: 6.228

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.